靶向治疗是胰腺癌综合治疗一个重要的组成部分。胰腺癌发生、发展过程中有许多分子可作为靶向治疗的靶点。但目前众多的靶向治疗药物中，只有小分子酪氨酸激酶抑制剂厄洛替尼在前瞻性对照研究中证明对晚期胰腺癌有效。不同于传统的细胞毒药物，胰腺癌靶向治疗的研究需综合考虑病人的异质性、选择适合的研究终点和研究设计。

Targeted therapy of pancreatic cancer        LOU Wen-hui. General Surgery, Zhongshan Hospital, Fudan University, Shanghai 200032, China
Abstract    Targeted therapy is a main part of comprehensive therapy for pancreatic cancer. During the tumerogenesis and development of pancreatic cancer, lots of molecular could be the target of targeted therapy. Among dozens of molecular agents, only small molecular tyrosine kinase inhibitor erlotinib is proven to be effective against advanced pancreatic cancer in prospective randomized study. Unlike traditional cytotoxic agent, several aspects need to be adjusted in the conduction of targeted therapy research, such as heterogeneity of patients, proper endpoint and design.